ESC 365 - Controversies in antithrombotic treatment for primary and secondary prevention

ESC Premium Access

Controversies in antithrombotic treatment for primary and secondary prevention

Event: ESC CONGRESS 2019

Topic: Cardiovascular Pharmacotherapy

Session type: Debate Session

Date: 3 September 2019

Time: 11:00 - 12:30

Session

6 presentations in this session

Aspirin is out for primary prevention of cardiovascular disease - PRO.

Speaker: Professor J. Armitage (Oxford, GB)

Aspirin is out for primary prevention of cardiovascular disease - CON.

Speaker: Professor C. Patrono (Rome, IT)

Aspirin is out for primary prevention of cardiovascular disease - Discussion.

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - PRO.

Speaker: Doctor J. Eikelboom (Hamilton, CA)

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - CON.

Speaker: Doctor T. Cuisset (Marseille, FR)

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - Discussion.

4 speakers from this session

Professor Jane Armitage

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

10 presentations

1 follower

Professor Carlo Patrono

Catholic University of the Sacred Heart, Rome (Italy)

4 presentations

0 follower

Doctor John William Eikelboom

McMaster University, Hamilton (Canada)

32 presentations

0 follower

Doctor Thomas Cuisset

AP-HM - Hospital La Timone, Marseille (France)

4 presentations

0 follower

This platform is supported by